Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27349839 | 0.82 | GPR119 (0.47) | GPR119 | |
| SCHEMBL27351545 | 0.81 | HTT (0.44) | CYP11B2KDM4EALDH1A1GAAHTT | |
| SCHEMBL27351552 | 0.73 | CYP1A2 (0.37) | ALDH1A1POLB | |
| SCHEMBL27351573 | 0.70 | HTT (0.36) | KDM4EALDH1A1GAAHTTSMN1; SMN2 | |
| SCHEMBL27351618 | 0.67 | CGAS (0.31) | — | |
| SCHEMBL27351563 | 0.67 | ADORA2B (0.31) | — | |
| SCHEMBL27351538 | 0.67 | CGAS (0.33) | CYP11B2 | |
| SCHEMBL27349835 | 0.65 | OPRM1 (0.57) | GPR119 | |
| SCHEMBL27349815 | 0.62 | GPR119 (0.49) | CYP11B2SMN1; SMN2GPR119 | |
| SCHEMBL27349812 | 0.62 | GPR119 (0.51) | KDM4EALDH1A1GAAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | CYP11B2 259/4885KDM4E 2028/4885ALDH1A1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.